menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'HTA' ×
John Doyle
Expectations for RWE are shaping the value conversation in healthcare. At this year’s ISPOR, we will explore what this trend means for pharma and how they can generate the most benefit from these studies.
Read More
Anke van Engen
How the Japanese government’s efforts to rein-in pharma spending will effect drug prices across the country.
Read More
Jeremy Broadis
Obtaining regional and local market access in the age of health technology assessments.
Read More
DeanSummerfield
Exploring the challenges HTA bodies face keeping pace with fast track approval paths and value as defined by the patient.
Read More
Anke van Engen
Slow uptake of PCSK9 inhibitors offers valuable lessons to sponsors about the importance of hard clinical data to win approval from payers.
Read More
Anke van Engen
How this relatively new US-based HTA framework could change the conversation about value and affordability.
Read More
Anke van Engen
Developers pursing accelerated pathways should work with payers to understand what evidence needs to be obtained to increase the chance of a positive recommendation.
Read More
John Doyle
John Doyle
This is the second in a 10 part series of trends impacting the biopharma industry.
Read More
Johan Maervoet
Exploring the benefits and limitations of oncology value frameworks.
Read More